COPENHAGEN, May 6 (Reuters) - Denmark’s Novo Nordisk posted a better-than-expected quarterly operating profit on Wednesday and kept its full-year outlook, as customers stocking up during the coronavirus pandemic boosted sales of its diabetes medicines.
Novo Nordisk, the world’s top maker of diabetes drugs, posted a first-quarter operating profit of 16.3 billion Danish crowns ($2.37 billion), compared to an average 14.2 billion expected by analysts. ($1 = 6.8867 Danish crowns) (Reporting by Stine Jacobsen)
Our Standards: The Thomson Reuters Trust Principles.